Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Cara Therapeutics, Inc. | d316484dex321.htm |
| EX-31.2 - EX-31.2 - Cara Therapeutics, Inc. | d316484dex312.htm |
| EX-31.1 - EX-31.1 - Cara Therapeutics, Inc. | d316484dex311.htm |
| 10-K - FORM 10-K - Cara Therapeutics, Inc. | d316484d10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| • | Registration Statement (Form S-3 No. 333-203072) of Cara Therapeutics Inc. |
| • | Registration Statement (Form S-8 No. 333-210096) of Cara Therapeutics Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc. |
| • | Registration Statement (Form S-8 No. 333-203057) of Cara Therapeutics Inc., pertaining to the 2014 Equity Incentive Plan of Cara Therapeutics Inc., and |
| • | Registration Statement (Form S-8 No. 333-193905) pertaining to the 2004 Stock Incentive Plan, as amended, and 2014 Equity Incentive Plan; |
of our report dated March 9, 2017, with respect to the financial statements of Cara Therapeutics Inc., included in this Annual Report (Form 10-K) of Cara Therapeutics Inc., for the year ended December 31, 2016.
/s/ Ernst & Young LLP
Stamford, Connecticut
March 9, 2017